A recent evidence-based review described the proposed clinical utility of UGT1A1 genotyping, as three recent studies they reviewed found statistically significant higher tumour response rates among individuals homozygous for a particular allele [21]. The gene discussed is UGT1A1; the disease is neoplasm.